176 related articles for article (PubMed ID: 21645226)
1. Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping.
Ogata K; Selvaraj SR; Miao HZ; Pipe SW
J Thromb Haemost; 2011 Jun; 9(6):1183-90. PubMed ID: 21645226
[TBL] [Abstract][Full Text] [Related]
2. Characterization of five associations of F8 missense mutations containing FVIII B domain mutations.
Jourdy Y; Nougier C; Roualdes O; Fretigny M; Durand B; Negrier C; Vinciguerra C
Haemophilia; 2016 Jul; 22(4):583-9. PubMed ID: 26915717
[TBL] [Abstract][Full Text] [Related]
3. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins.
Pipe SW; Kaufman RJ
J Biol Chem; 1996 Oct; 271(41):25671-6. PubMed ID: 8810344
[TBL] [Abstract][Full Text] [Related]
4. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.
Jacquemin M; Lavend'homme R; Benhida A; Vanzieleghem B; d'Oiron R; Lavergne JM; Brackmann HH; Schwaab R; VandenDriessche T; Chuah MK; Hoylaerts M; Gilles JG; Peerlinck K; Vermylen J; Saint-Remy JM
Blood; 2000 Aug; 96(3):958-65. PubMed ID: 10910910
[TBL] [Abstract][Full Text] [Related]
5. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII.
Amano K; Sarkar R; Pemberton S; Kemball-Cook G; Kazazian HH; Kaufman RJ
Blood; 1998 Jan; 91(2):538-48. PubMed ID: 9427707
[TBL] [Abstract][Full Text] [Related]
6. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo.
Pipe SW; Eickhorst AN; McKinley SH; Saenko EL; Kaufman RJ
Blood; 1999 Jan; 93(1):176-83. PubMed ID: 9864159
[TBL] [Abstract][Full Text] [Related]
7. Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII.
Wei W; Zheng C; Zhu M; Zhu X; Yang R; Misra S; Zhang B
Sci Rep; 2017 Mar; 7():45033. PubMed ID: 28327546
[TBL] [Abstract][Full Text] [Related]
8. Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM(-)) and G1948D (CRM(r)).
David D; Saenko EL; Santos IM; Johnson DJ; Tuddenham EG; McVey JH; Kemball-Cook G
Br J Haematol; 2001 Jun; 113(3):604-15. PubMed ID: 11380445
[TBL] [Abstract][Full Text] [Related]
9. Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations.
Loomans JI; van Velzen AS; Eckhardt CL; Peters M; Mäkipernaa A; Holmstrom M; Brons PP; Dors N; Haya S; Voorberg J; van der Bom JG; Fijnvandraat K
J Thromb Haemost; 2017 Feb; 15(2):246-254. PubMed ID: 27943580
[TBL] [Abstract][Full Text] [Related]
10. Effect of F8 B domain gene variants on synthesis, secretion, activity and stability of factor VIII protein.
Pahl S; Pavlova A; Driesen J; Oldenburg J
Thromb Haemost; 2014 Jan; 111(1):58-66. PubMed ID: 24108539
[TBL] [Abstract][Full Text] [Related]
11. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
[TBL] [Abstract][Full Text] [Related]
12. [Molecular analysis of a patient with hemophilia A caused by FVIII His99Arg mutation].
Qin HH; Wang XF; Ding QL; Lu YL; Dai J; Xi XD; Wang HL
Zhonghua Xue Ye Xue Za Zhi; 2011 Sep; 32(9):587-91. PubMed ID: 22338150
[TBL] [Abstract][Full Text] [Related]
13. Bioengineering of coagulation factor VIII for improved secretion.
Miao HZ; Sirachainan N; Palmer L; Kucab P; Cunningham MA; Kaufman RJ; Pipe SW
Blood; 2004 May; 103(9):3412-9. PubMed ID: 14726380
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development.
Repessé Y; Slaoui M; Ferrandiz D; Gautier P; Costa C; Costa JM; Lavergne JM; Borel-Derlon A
J Thromb Haemost; 2007 Jul; 5(7):1469-76. PubMed ID: 17445092
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of an in vitro cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the F8 gene in women with isolated factor VIII:C deficiency.
Roualdes O; Nougier C; Fretigny M; Talagrand E; Durand B; Negrier C; Vinciguerra C
Haemophilia; 2015 May; 21(3):e202-e209. PubMed ID: 25708597
[TBL] [Abstract][Full Text] [Related]
16. Functional mapping of the A2 domain from human factor VIII.
Plantier JL; Saboulard D; Pellequer JL; Négrier C; Delcourt M
Thromb Haemost; 2012 Feb; 107(2):315-27. PubMed ID: 22234396
[TBL] [Abstract][Full Text] [Related]
17. Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A.
Roth SD; Schüttrumpf J; Milanov P; Abriss D; Ungerer C; Quade-Lyssy P; Simpson JC; Pepperkok R; Seifried E; Tonn T
PLoS One; 2012; 7(9):e44505. PubMed ID: 22973456
[TBL] [Abstract][Full Text] [Related]
18. Factor VIII Antigen, Activity, and Mutations in Hemophilia A.
Nair PS; Shetty S; Ghosh K
Clin Appl Thromb Hemost; 2016 May; 22(4):381-5. PubMed ID: 25550078
[TBL] [Abstract][Full Text] [Related]
19. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.
Pashov AD; Calvez T; Gilardin L; Maillère B; Repessé Y; Oldenburg J; Pavlova A; Kaveri SV; Lacroix-Desmazes S
Haemophilia; 2014 Mar; 20(2):176-84. PubMed ID: 24118514
[TBL] [Abstract][Full Text] [Related]
20. Expression and characterization of a codon-optimized blood coagulation factor VIII.
Shestopal SA; Hao JJ; Karnaukhova E; Liang Y; Ovanesov MV; Lin M; Kurasawa JH; Lee TK; Mcvey JH; Sarafanov AG
J Thromb Haemost; 2017 Apr; 15(4):709-720. PubMed ID: 28109042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
